gliclazide and Fasting Hypoglycemia studies

Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.

Fasting Hypoglycemia: HYPOGLYCEMIA expressed in the postabsorptive state, after prolonged FASTING, or an overnight fast.

Research Excerpts

Excerpt	Relevance	Reference
"Patients treated with either gliclazide or DPP-4 inhibitors while fasting during Ramadan have similarly low risks of experiencing symptomatic hypoglycemia."	8.91	Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus DPP-4 inhibitors during Ramadan: A meta-analytical approach. ( Abdel-Rahim, A; Al-Sifri, S; Mbanya, JC; Satman, I, 2015)
"Initiation of iGlarLixi resulted in similar TIR, A1C, FPG, weight and hypoglycemia compared with the more affordable option of starting iGlar + gliclazide in adults of South Asian origin with T2D."	5.51	Randomized Comparison of Initiating the Fixed-Ratio Combination of iGlarLixi or Biosimilar Insulin Glargine Together With Gliclazide in Participants of South Asian Origin With Type 2 Diabetes: VARIATION 2 SA Trial. ( Aronson, R; Bajaj, HS; Bansal, N; Bhela, JS; Brown, RE; Chu, L; Dhillon, G; Gupta, R; Khandwala, H; Padda, JK; Venn, K, 2022)
"Several observational studies were conducted with vildagliptin in patients with type 2 diabetes mellitus (T2DM) fasting during Ramadan, showing significantly lower incidences of hypoglycemia with vildagliptin versus sulfonylureas, including gliclazide."	5.19	A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study. ( Abdallah, K; Hassanein, M; Schweizer, A, 2014)
"Patients treated with either gliclazide or DPP-4 inhibitors while fasting during Ramadan have similarly low risks of experiencing symptomatic hypoglycemia."	4.91	Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus DPP-4 inhibitors during Ramadan: A meta-analytical approach. ( Abdel-Rahim, A; Al-Sifri, S; Mbanya, JC; Satman, I, 2015)
"Compared with other oral insulinotropic agents, gliclazide significantly reduced HbA1c with no difference regarding hypoglycemia risk."	4.91	Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents. ( Chan, SP; Colagiuri, S, 2015)
"Included were randomized studies of at least 12 weeks duration with the following outcomes: HbA1c change, incidence of severe hypoglycemia, weight change, cardiovascular events and/or mortality when comparing gliclazide with other oral blood glucose lowering drugs."	4.90	Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials. ( Bilo, HJ; de Bock, GH; Gans, RO; Groenier, KH; Houweling, ST; Kleefstra, N; Landman, GW; van Dijk, PR; van Hateren, KJ, 2014)
"The risk for hypoglycemia when taking glyburide compared with modified-release gliclazide remains to be established in older adults in routine care."	3.81	The Hypoglycemic Risk of Glyburide (Glibenclamide) Compared with Modified-Release Gliclazide. ( Clemens, KK; Dixon, SN; Fleet, JL; Garg, AX; Hramiak, I; McArthur, E, 2015)
"Severe hypoglycemia was strongly associated with increased risks of a range of adverse clinical outcomes."	2.75	Severe hypoglycemia and risks of vascular events and death. ( Billot, L; Chalmers, J; de Galan, BE; Grobbee, DE; Heller, S; Kengne, AP; Li, Q; MacMahon, S; Marre, M; Neal, B; Ninomiya, T; Patel, A; Woodward, M; Zoungas, S, 2010)
"In patients with type 2 diabetes, the effects of intensive glucose control on vascular outcomes remain uncertain."	2.73	Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. ( Billot, L; Bompoint, S; Chalmers, J; Cooper, M; de Galan, BE; Glasziou, P; Grobbee, D; Hamet, P; Harrap, S; Heller, S; Joshi, R; Liu, L; MacMahon, S; Mancia, G; Marre, M; Mogensen, CE; Neal, B; Pan, C; Patel, A; Poulter, N; Rodgers, A; Travert, F; Williams, B; Woodward, M, 2008)
"Treatment with nateglinide plus metformin for up to 12 months was not associated with weight gain."	2.73	Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results. ( Collober-Maugeais, C; Cressier, F; Pecher, E; Ristic, S; Tang, P, 2007)
" We sought to estimate individual beneficial and adverse effects of intensive glucose control in patients with type 2 diabetes."	1.43	Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes. ( Chalmers, J; Grobbee, DE; Harrap, S; Heller, S; Mancia, G; Marre, M; Poulter, N; van der Graaf, Y; van der Leeuw, J; Visseren, FL; Woodward, M; Zoungas, S, 2016)
"Gliclazide or metformin-treated patients demonstrated lesser mortality risk than glibenclamide-treated ones in all four evaluation models, but age and duration stratification can influence this phenomenon in case of "first prescription model"."	1.40	Evaluation approach can significantly influence oral glucose-lowering drugs total mortality risks in retrospective cohorts of type 2 diabetes mellitus patients. ( Khalangot, M; Kovtun, V, 2014)
"A 74-year-old woman with type 2 diabetes mellitus who had been treated with a sulfonylurea for 6 years began experiencing frequent episodes of hypoglycemia."	1.34	Insulinoma causing hypoglycemia in a patient with type 2 diabetes. ( Chang, WH; Chen, TL; Lei, WY; Wang, CY; Wang, TE; Yang, TL, 2007)

Research

Studies (47)

Authors

Clinical Trials (14)

Trial Overview

Trial Outcomes

Coefficient of Variation at 26 Weeks Minus Coefficient of Variation at Baseline

Timeframe	Studies, this research(%)	All Research%
pre-1990	3 (6.38)	18.7374
1990's	7 (14.89)	18.2507
2000's	15 (31.91)	29.6817
2010's	19 (40.43)	24.3611
2020's	3 (6.38)	2.80

Authors	Studies
Bajaj, HS	1
Chu, L	1
Bansal, N	1
Brown, RE	1
Dhillon, G	1
Gupta, R	1
Bhela, JS	1
Padda, JK	1
Khandwala, H	1
Venn, K	1
Aronson, R	1
Kelty, E	1
Tran, DD	1
Atkinson, A	1
Preen, DB	1
Havard, A	1
Mifsud, S	1
Schembri, EL	1
Fava, S	1
Saberi, M	1
Ramazani, Z	1
Rashidi, H	1
Saberi, A	1
Raslan, IA	1
McDonald, EG	1
Lee, TC	1
Gopal-Kothandapani, JS	1
Wright, KP	1
Sithambaram, S	1
Natarajan, A	1
Douros, A	1
Yin, H	1
Yu, OHY	1
Filion, KB	1
Azoulay, L	1
Suissa, S	1
Landman, GW	2
de Bock, GH	1
van Hateren, KJ	2
van Dijk, PR	1
Groenier, KH	2
Gans, RO	1
Houweling, ST	1
Bilo, HJ	1
Kleefstra, N	2
Winkler, G	1
Hassanein, M	2
Abdallah, K	1
Schweizer, A	1
Zhao, F	1
Ma, YF	1
Wen, JX	1
DU, YF	1
Li, CL	1
Li, GW	1
Khalangot, M	1
Kovtun, V	1
Clemens, KK	1
McArthur, E	1
Dixon, SN	1
Fleet, JL	1
Hramiak, I	1
Garg, AX	1
Mbanya, JC	1
Al-Sifri, S	1
Abdel-Rahim, A	1
Satman, I	1
Chan, SP	1
Colagiuri, S	1
Oei, E	1
Samad, N	1
Visser, A	1
Chowdhury, TA	2
Fan, SL	1
Wong, MG	1
Perkovic, V	1
Chalmers, J	5
Woodward, M	5
Li, Q	2
Cooper, ME	1
Hamet, P	3
Harrap, S	3
Heller, S	4
MacMahon, S	4
Mancia, G	4
Marre, M	4
Matthews, D	1
Neal, B	4
Poulter, N	4
Rodgers, A	2
Williams, B	2
Zoungas, S	4
van der Leeuw, J	1
Visseren, FL	1
van der Graaf, Y	1
Grobbee, DE	3
van Dijk, P	1
Bouma, A	1
Bilo, H	1
Patel, A	3
Billot, L	2
Cooper, M	2
Glasziou, P	1
Grobbee, D	1
Liu, L	1
Mogensen, CE	1
Pan, C	1
Bompoint, S	1
de Galan, BE	3
Joshi, R	1
Travert, F	2
Walker, J	1
White, R	1
Vale, A	1
Elliott, S	2
Wass, J	1
Reynolds, J	1
Devendra, D	1
Gohel, B	1
Bravis, V	1
Hui, E	1
Salih, S	1
Mehar, S	1
Anderson, C	1
Dufouil, C	1
Pillai, A	1
Hackett, M	1
Heller, SR	1
Lisheng, L	1
Pan, CY	1
Ling, GR	1
Singh, K	1
Wong, SY	1
Toh, VK	1
Ninomiya, T	1
Kengne, AP	1
Gupta, PS	1
Green, AN	1
Ragia, G	1
Tavridou, A	1
Petridis, I	1
Manolopoulos, VG	1
Langford, NJ	1
Krentz, AJ	1
Martin, U	1
Ferner, RE	1
Crawford, BA	1
Perera, C	1
Schernthaner, G	1
Grimaldi, A	1
Di Mario, U	1
Drzewoski, J	1
Kempler, P	1
Kvapil, M	1
Novials, A	1
Rottiers, R	1
Rutten, GE	1
Shaw, KM	1
Satyanarayana, S	1
Sekhar, JR	1
Kumar, KE	1
Shannika, LB	1
Rajanna, B	1
Rajanna, S	1
Chan, HY	1
Tiu, SC	1
Chan, OK	1
Lei, WY	1
Wang, TE	1
Chen, TL	1
Chang, WH	1
Yang, TL	1
Wang, CY	1
Ristic, S	1
Collober-Maugeais, C	1
Cressier, F	1
Tang, P	1
Pecher, E	1
Sener, A	1
Akkan, AG	1
Malaisse, WJ	1
Tessier, D	1
Dawson, K	1
Tétrault, JP	1
Bravo, G	1
Meneilly, GS	1
Braatvedt, GD	1
van Staa, T	1
Abenhaim, L	1
Monette, J	1
Paroni, R	1
Comuzzi, B	1
Arcelloni, C	1
Brocco, S	1
de Kreutzenberg, S	1
Tiengo, A	2
Ciucci, A	1
Beck-Peccoz, P	1
Genovese, S	1
da Tos, V	1
Maran, A	1
Vigili de Kreutzenberg, S	1
Marchetto, S	1
Tadiotto, F	1
Bettio, M	1
Marescotti, MC	1
Del Prato, S	1
Abad, S	1
Moachon, L	1
Blanche, P	1
Bavoux, F	1
Sicard, D	1
Salmon-Céron, D	1
De Vigan, C	1
Delporte, MP	1
Thomas, M	1
Perrault, M	1
Grandmottet, P	1
Narboni, G	1
Schwager, JC	1
Betchel, P	1
Sandoz, M	1
Vandel, B	1
de Lavenne, P	1
Peijnenburg, MA	1
Shenfield, GM	1
Boutagy, JS	1
Webb, C	1
Archambeaud-Mouveroux, F	1
Nouaille, Y	1
Nadalon, S	1
Treves, R	1
Merle, L	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Variability of Glucose Assessed in a Randomized Trial Comparing the Initiation of A Treatment Approach With Biosimilar Basal Insulin Analog Or a Titratable iGlarLixi combinatioN in Type 2 Diabetes Among South Asian Subjects (VARIATION 2 SA Trial)[NCT03819790]	Phase 4	119 participants (Actual)	Interventional	2018-10-02	Completed
A Double Blind, Double Dummy, Randomised, Multi-centre Study to Assess the Tolerability and Efficacy Profile of Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan[NCT01758380]	Phase 4	557 participants (Actual)	Interventional	2013-01-31	Completed
Action in Diabetes and Vascular Disease Preterax and Diamicron MR Controlled Evaluation Post Trial Observational Study[NCT00949286]		8,494 participants (Actual)	Observational	2010-01-31	Completed
ADVANCE - Action in Diabetes and Vascular Disease: Preterax and Diamicron - MR Controlled Evaluation[NCT00145925]	Phase 3	11,140 participants (Actual)	Interventional	2001-06-30	Completed
Carotid Intimae-media Thickness (CIMT) and Carotid Plaque (CP) Presence as Risk Markers of Cardiovascular Disease at the Time of Type 2 Diabetes Diagnosis[NCT01898572]		200 participants (Anticipated)	Observational	2012-01-31	Active, not recruiting
Low-dose Colchicine Intervention in Patients With Type 2 Diabetes Mellitus and Microalbuminuria: Chongqing Study[NCT02035891]		160 participants (Actual)	Interventional	2013-12-31	Active, not recruiting
Effect of Anti-diabetic Drugs on Glycemic Variability. A Comparison Between Gliclazide MR (Modified Release) and Dapagliflozin on Glycemic Variability Measured by Continuous Glucose Monitoring (CGM) in Patients With Uncontrolled Type 2 Diabetes[NCT02925559]	Phase 4	135 participants (Actual)	Interventional	2016-10-31	Completed
Effectiveness and Tolerability of Novel, Initial Triple Combination Therapy With Xigduo (Dapagliflozin Plus Metformin) and Saxagliptin vs. Conventional Stepwise add-on Therapy in Drug-naïve Patients With Type 2 Diabetes[NCT02946632]	Phase 3	104 participants (Anticipated)	Interventional	2016-12-31	Not yet recruiting
Dietary Intervention in Type-2 Diabetics and Pre-Diabetics Emphasizing Personalized Carbohydrate Intake[NCT02519309]		465 participants (Actual)	Interventional	2015-08-31	Completed
Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population: Implication on Diabetes Complication Risk?[NCT02879409]		150 participants (Anticipated)	Interventional	2016-11-30	Active, not recruiting
FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR[NCT01524705]	Phase 4	102 participants (Actual)	Interventional	2012-08-31	Completed
Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial.[NCT01991197]	Phase 2	20 participants (Actual)	Interventional	2014-04-30	Completed
A Comparison of Strict Glucose Control With Usual Care at the Time of Islet Cell Transplantation[NCT01123122]		0 participants (Actual)	Interventional	2011-09-30	Withdrawn
Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetic Patients With Coronary Artery Disease[NCT01604213]	Phase 4	60 participants (Actual)	Interventional	2012-09-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

The change in the coefficient of variation (CV) of continuous glucose readings, as assessed by Continuous Glucose Monitoring (CGM) (NCT01524705)
Timeframe: At baseline, 6 months of intervention

HbA1C Levels

Intervention	percentage (Mean)
Insulin Glargine, Metformin, Exenatide	-2.43
Insulin Glargine, Metformin, Prandial Insulin	0.44

% of glycosylated hemoglobin in whole blood at 26 weeks (NCT01524705)
Timeframe: Baseline vs 26 weeks

Number of Participants With Hypoglycemia

Intervention	% of HbA1C (Mean)
Insulin Glargine, Metformin, Exenatide	7.1
Insulin Glargine, Metformin, Prandial Insulin	7.2

Severe hypoglycemia-documented glucose <50mg/dl (participant journal), and hypoglycemic attacks requiring hospitalization, or treatment by emergency personnel. (NCT01524705)
Timeframe: 26 weeks

Weight Change During Trial

Intervention	Participants (Count of Participants)
Insulin Glargine, Metformin, Exenatide	0
Insulin Glargine, Metformin, Prandial Insulin	0

Weight in kg at 26 weeks minus weight at baseline. (NCT01524705)
Timeframe: Baseline vs 26 weeks

The Change in Levels of High Sensitivity C-reactive Protein From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.

Intervention	kg (Mean)
Insulin Glargine, Metformin, Exenatide	-4.8
Insulin Glargine, Metformin, Prandial Insulin	0.7

High sensitivity C-reactive protein (range 0 - no maximum) (NCT01991197)
Timeframe: 16 weeks

The Change in Levels of Serum Glucose From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.

Intervention	µg/ml (Median)
Sitagliptin	0
Gliclazide	8.4

The change in glucose from baseline to 16 weeks (NCT01991197)
Timeframe: 16 weeks

The Change in Levels of Systolic Blood Pressure From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.

Intervention	mmol/L (Median)
Sitagliptin	-0.2
Gliclazide	-0.1

The change in systolic blood pressure from baseline to 16 weeks measured in kg (NCT01991197)
Timeframe: 16 weeks

The Change in Levels of Total Cholesterol From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.

Intervention	mmHg (Median)
Sitagliptin	4
Gliclazide	-9

The change in total cholesterol from baseline to 16 weeks (NCT01991197)
Timeframe: 16 weeks

The Change in PASI From Baseline to 32 Weeks in Psoriasis Patients With Type 2 Diabetes Treated With Sitagliptin Compared to Patients Treated With Gliclazide.

Intervention	mmol/L (Median)
Sitagliptin	0.1
Gliclazide	-0.1

Psoriasis area and severity index 0-72, higher score worse outcome (NCT01991197)
Timeframe: baseline and 32 weeks

The Change in the Psoriasis Area and Severity Index (PASI) From Baseline to 16 Weeks in Psoriasis Patients With Type 2 Diabetes Treated With Sitagliptin Compared to Patients Treated With Gliclazide.

Intervention	score on a scale (Median)
Sitagliptin	3
Gliclazide	1.8

Psoriasis area and severity index (0-72), higher scores worse outcome (NCT01991197)
Timeframe: 16 weeks

The Change in Weight From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.

Intervention	score on a scale (Median)
Sitagliptin	9.5
Gliclazide	9.4

The change in weight from baseline to 16 weeks measured in kg (NCT01991197)
Timeframe: 16 weeks

The Effect of Treatment With Sitagliptin and With Gliclazide From Baseline to 16 Weeks on the Change in Dipeptidyl Peptidase-4 Levels in the Skin (in a Sub-group of Participants Willing to Undergo Skin Biopsies).

Intervention	kg (Median)
Sitagliptin	-0.5
Gliclazide	-0.6

Dipeptidyl peptidase-4 levels levels in skin (0-no maximum) (NCT01991197)
Timeframe: 16 weeks

The Effect of Treatment With Sitagliptin and With Gliclazide From Baseline to 16 Weeks on the Change in Interleukin-17 Levels in the Skin (in a Sub-group of Participants Willing to Undergo Skin Biopsies).

The Effects of Treatment With Sitagliptin and Treatment With Gliclazide From Baseline to 16 Weeks on Serum Levels Interleukin-17.

Intervention	dCt (Median)
Gliclazide	-1.12
Sitagliptin	0

Intervention	dCt (Median)
Sitagliptin	3.41
Gliclazide	2.09

"Secondary outcomes:~The change in serum concentrations of the cytokine interleukin-17 (IL-17) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks

The Effects of Treatment With Sitagliptin and Treatment With Gliclazide From Baseline to 16 Weeks on Serum Levels Interleukin-23.

Intervention	pg/ml (Median)
Sitagliptin	0
Gliclazide	0

"Secondary outcomes:~The change in serum concentrations of the cytokine interleukin-23 (IL-23) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks

The Effects of Treatment With Sitagliptin and Treatment With Gliclazide on the Change in Serum Leptin From Baseline to 16 Weeks.

Intervention	pg/ml (Median)
Sitagliptin	0
Gliclazide	0

"Secondary outcomes:~The change in serum concentrations of the adipokine leptin Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks

The Effects of Treatment With Sitagliptin and Treatment With Gliclazide on the Serum Cytokine Tumour Necrosis Factor Alpha.

Intervention	pg/ml (Median)
Sitagliptin	-0.07
Gliclazide	0.43

"Secondary outcomes:~The change in serum concentrations of the cytokines tumour necrosis factor alpha (TNFα) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks

The Number of Patricipants in the Sitagliptin and Gliclazide Arms With Adverse Events at 32 Weeks.

Intervention	pg/ml (Median)
Sitagliptin	0
Gliclazide	0

"Dosage: Sitagliptin: 100mg daily, or 50mg daily for participants with moderate kidney disease Gliclazide: 80-320 mg daily.~Secondary outcomes: the number participants with adverse events." (NCT01991197)
Timeframe: 32 weeks

The Change in Quality of Life Scores From Baseline to 16 Weeks in the Sitagliptin and Gliclazide Arms.

Intervention	Participants (Count of Participants)
Sitagliptin	6
Gliclazide	10

"Dermatology life quality index (a skin related quality of life measure) (0-10), higher score worse outcome EQ-5D Euroqol 5 item quality of life index comprising 5 dimensions mobility, self-care, usual activities, pain, anxiety. An index can be derived from these 5 dimensions by conversion with a table of scores. The maximum score of 1 indicates the best health state and minimum score indicating the worst health outcome -0.594.~HADS Hospital anxiety and depression scale 0-16 for anxiety and 0-16 for depression, higher score worse outcome HAQ-8 Stanford 8 item disability scale. Scoring is from 0 (without any difficulty) to 3 (unable to do). The 8 scores from the 8 sections are summed and divided by 8. The result is the disability index (range 0-3 with 25 possible values). A" (NCT01991197)
Timeframe: 16 weeks

The Effects of Treatment With Sitagliptin and Treatment With Gliclazide on Other Efficacy Endpoints.

Intervention	score on a scale (Median)
	DLQI	HAQ-8	HADS Anxiety	HADS Depression	EQ-5D
Gliclazide	-1.0	0.0	0	0	-0.2
Sitagliptin	0.0	0.0	-1	0	0

"Secondary outcomes:~d. number or participants who acheived a greater than 50% reduction in PASI from baseline (PASI-50); e. number of participants who achieved PASI-75 and PASI-90." (NCT01991197)
Timeframe: 16 weeks

Article	Year
Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials. PloS one, 2014, Volume: 9, Issue:2 Topics: Administration, Oral; Blood Glucose; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2	2014
[The use of gliclazide in individualized sulfonylurea therapy]. Orvosi hetilap, 2014, Apr-06, Volume: 155, Issue:14 Topics: Gliclazide; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin-Secreting Cells; Sulfonylurea Compoun	2014
Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus DPP-4 inhibitors during Ramadan: A meta-analytical approach. Diabetes research and clinical practice, 2015, Volume: 109, Issue:2 Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Gliclazide; H	2015
Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents. Diabetes research and clinical practice, 2015, Volume: 110, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glicl	2015
[Hypoglycemia]. Praxis, 2011, Oct-19, Volume: 100, Issue:21 Topics: Algorithms; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gliclazide; Humans;	2011

Article	Year
Randomized Comparison of Initiating the Fixed-Ratio Combination of iGlarLixi or Biosimilar Insulin Glargine Together With Gliclazide in Participants of South Asian Origin With Type 2 Diabetes: VARIATION 2 SA Trial. Canadian journal of diabetes, 2022, Volume: 46, Issue:5 Topics: Adult; Aged; Biosimilar Pharmaceuticals; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations	2022
A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study. Vascular health and risk management, 2014, Volume: 10 Topics: Adamantane; Asia; Biomarkers; Blood Glucose; Body Weight; Counseling; Diabetes Mellitus, Type 2; Dip	2014
Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON. Diabetes care, 2016, Volume: 39, Issue:5 Topics: Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Drug Combin	2016
Hypoglycemia in Frail Elderly Patients With Type 2 Diabetes Mellitus Treated With Sulfonylurea. Journal of diabetes science and technology, 2017, Volume: 11, Issue:2 Topics: Aged; Aged, 80 and over; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Female; Frail Eld	2017
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England journal of medicine, 2008, Jun-12, Volume: 358, Issue:24 Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab	2008
Severe hypoglycemia and risks of vascular events and death. The New England journal of medicine, 2010, Oct-07, Volume: 363, Issue:15 Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glicla	2010
Severe hypoglycemia and risks of vascular events and death. The New England journal of medicine, 2010, Oct-07, Volume: 363, Issue:15 Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glicla	2010
Severe hypoglycemia and risks of vascular events and death. The New England journal of medicine, 2010, Oct-07, Volume: 363, Issue:15 Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glicla	2010
Severe hypoglycemia and risks of vascular events and death. The New England journal of medicine, 2010, Oct-07, Volume: 363, Issue:15 Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glicla	2010
GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. European journal of clinical investigation, 2004, Volume: 34, Issue:8 Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gliclazide; Glycated Hemoglobin; Humans; Hyp	2004
Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results. Diabetes, obesity & metabolism, 2007, Volume: 9, Issue:4 Topics: Aged; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Femal	2007
Glibenclamide vs gliclazide in type 2 diabetes of the elderly. Diabetic medicine : a journal of the British Diabetic Association, 1994, Volume: 11, Issue:10 Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gliclazide; Glyburide; Humans; Hypoglycemia;	1994
Mechanisms of acute and chronic hypoglycemic action of gliclazide. Acta diabetologica, 2000, Volume: 37, Issue:4 Topics: Acute Disease; Blood Glucose; C-Peptide; Chronic Disease; Diabetes Mellitus, Type 2; Gliclazide; Glu	2000

Article	Year
Maternal and Neonatal Health Outcomes Associated with the Use of Gliclazide and Metformin for the Treatment of Diabetes in Pregnancy: A Record Linkage Study. Diabetes technology & therapeutics, 2020, Volume: 22, Issue:2 Topics: Abnormalities, Drug-Induced; Adult; Diabetes, Gestational; Female; Gliclazide; Hospitalization; Huma	2020
A case of severe relapsing sulphonylurea-induced hypoglycaemia. BMJ case reports, 2019, Dec-02, Volume: 12, Issue:12 Topics: Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypoglycemia; Middle Aged; Renal Insufficienc	2019
The Effect of CYP2C9 Genotype Variants in Type 2 Diabetes on the Pharmacological Effectiveness of Sulfonylureas, Diabetic Retinopathy, and Nephropathy. Vascular health and risk management, 2020, Volume: 16 Topics: Biomarkers; Blood Glucose; Cytochrome P-450 CYP2C9; Diabetes Mellitus, Type 2; Diabetic Nephropathie	2020
Missed Opportunities for Deprescription: A Teachable Moment. JAMA internal medicine, 2017, 07-01, Volume: 177, Issue:7 Topics: Aged, 80 and over; Deprescriptions; Diabetes Complications; Diabetes Mellitus; Drug Therapy, Combina	2017
Dilemma of diagnosing sulphonylurea overdose in children: deliberations and considerations before reaching a diagnosis. BMJ case reports, 2017, Aug-28, Volume: 2017 Topics: Adolescent; Blood Glucose; Diagnosis, Differential; Drug Overdose; Emergency Service, Hospital; Fema	2017
Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events. Diabetes care, 2017, Volume: 40, Issue:11 Topics: Aged; Aged, 80 and over; Body Mass Index; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus	2017
Parsimonious model for blood glucose level monitoring in type 2 diabetes patients. Biomedical and environmental sciences : BES, 2014, Volume: 27, Issue:7 Topics: Adult; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Female; Gliclazide;	2014
Evaluation approach can significantly influence oral glucose-lowering drugs total mortality risks in retrospective cohorts of type 2 diabetes mellitus patients. Current diabetes reviews, 2014, Volume: 10, Issue:5 Topics: Diabetes Mellitus, Type 2; Gliclazide; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; Metform	2014
The Hypoglycemic Risk of Glyburide (Glibenclamide) Compared with Modified-Release Gliclazide. Canadian journal of diabetes, 2015, Volume: 39, Issue:4 Topics: Aged; Aged, 80 and over; Cohort Studies; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Fem	2015
Use of continuous glucose monitoring in patients with diabetes on peritoneal dialysis: poor correlation with HbA1c and high incidence of hypoglycaemia. Diabetic medicine : a journal of the British Diabetic Association, 2016, Volume: 33, Issue:9 Topics: Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2;	2016
Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes. Diabetologia, 2016, Volume: 59, Issue:12 Topics: Aged; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Combinations	2016
Unexplained severe hypoglycaemia in hospital: a difficult diagnostic challenge. British journal of clinical pharmacology, 2009, Volume: 67, Issue:2 Topics: Aged; Cholecystectomy; Diabetes Mellitus, Type 2; Gliclazide; Humans; Hypertension; Hypoglycemia; Ma	2009
Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan. International journal of clinical practice, 2009, Volume: 63, Issue:10 Topics: Adamantane; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fastin	2009
Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Diabetologia, 2009, Volume: 52, Issue:11 Topics: Aged; Antihypertensive Agents; Cognition; Cognition Disorders; Diabetes Mellitus, Type 2; Diabetic A	2009
Severe neuroglycopaenia secondary to severe hypoglycaemia from serendipitous overdose of gliclazide without adrenergic or autonomic response. Diabetic medicine : a journal of the British Diabetic Association, 2009, Volume: 26, Issue:11 Topics: Blood Glucose; Drug Overdose; Gliclazide; Humans; Hypoglycemia; Hypoglycemic Agents; Male	2009
Association of KCNJ11 E23K gene polymorphism with hypoglycemia in sulfonylurea-treated type 2 diabetic patients. Diabetes research and clinical practice, 2012, Volume: 98, Issue:1 Topics: Adult; Aged; Alleles; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C9; Diabetes Mellitus, Typ	2012
Severe relapsing sulphonylurea-induced hypoglycaemia: a diagnostic and therapeutic challenge. Postgraduate medical journal, 2003, Volume: 79, Issue:928 Topics: Female; Gliclazide; Humans; Hypoglycemia; Hypoglycemic Agents; Middle Aged; Recurrence	2003
Octreotide treatment for sulfonylurea-induced hypoglycaemia. The Medical journal of Australia, 2004, May-17, Volume: 180, Issue:10 Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Gliclazide; Glyburide; Humans; Hypoglycemia; Hypogly	2004
Influence of selenium (antioxidant) on gliclazide induced hypoglycaemia/anti hyperglycaemia in normal/alloxan-induced diabetic rats. Molecular and cellular biochemistry, 2006, Volume: 283, Issue:1-2 Topics: Administration, Oral; Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Experimental; Drug Th	2006
Dual aetiologies for hyperinsulinaemic hypoglycaemia in one patient. Hong Kong medical journal = Xianggang yi xue za zhi, 2007, Volume: 13, Issue:1 Topics: Adult; Gliclazide; Humans; Hyperinsulinism; Hypoglycemia; Hypoglycemic Agents; Insulinoma; Male; Pan	2007
Insulinoma causing hypoglycemia in a patient with type 2 diabetes. Journal of the Formosan Medical Association = Taiwan yi zhi, 2007, Volume: 106, Issue:5 Topics: Aged; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hyperinsulinism; Hypoglycemia; Hypoglyc	2007
Standardized procedure for the assay and identification of hypoglycemic sulfonylureas in human plasma. Acta diabetologica, 1995, Volume: 32, Issue:1 Topics: Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Drug Monitoring; Forensic Medicine;	1995
Octreotide for the treatment of sulphonylurea induced hypoglycaemia in type 2 diabetes. The New Zealand medical journal, 1997, May-23, Volume: 110, Issue:1044 Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Gliclazide; Hormones; Humans; Hypoglycemia; Hypogl	1997
Rates of hypoglycemia in users of sulfonylureas. Journal of clinical epidemiology, 1997, Volume: 50, Issue:6 Topics: Adult; Aged; Chlorpropamide; Female; Gliclazide; Glipizide; Glyburide; Humans; Hypoglycemia; Hypogly	1997
Glimepiride: new preparation. Just another hypoglycaemic sulphonylurea agent. Prescrire international, 1998, Volume: 7, Issue:36 Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Evalua	1998
Comparison of capillary electrophoresis with HPLC for diagnosis of factitious hypoglycemia. Clinical chemistry, 2000, Volume: 46, Issue:11 Topics: Adult; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Drug Overdose; Electrophores	2000
Possible interaction between gliclazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia. British journal of clinical pharmacology, 2001, Volume: 52, Issue:4 Topics: Anti-Infective Agents; Antifungal Agents; Diabetes Complications; Diabetes Mellitus; Drug Interactio	2001
[Hypoglycemic complications of oral drug therapy of diabetes mellitus. 21 cases]. La Nouvelle presse medicale, 1976, Apr-03, Volume: 5, Issue:14 Topics: Age Factors; Aged; Diabetes Mellitus; Diabetic Coma; Drug Interactions; Female; Gliclazide; Glyburid	1976
[3 cases of hypoglycemia during treatment with gliclazide (1): contribution of phaarmocokinetics to the development of pathogenetic hypotheses]. Annales de medecine interne, 1977, Volume: 128, Issue:10 Topics: Adult; Aged; Female; Gliclazide; Humans; Hypoglycemia; Male; Sulfonylurea Compounds	1977
[Sulfonylurea preparations and hypoglycemia]. Nederlands tijdschrift voor geneeskunde, 1992, Jan-25, Volume: 136, Issue:4 Topics: Gliclazide; Humans; Hypoglycemia; Probability	1992
A screening test for detecting sulfonylureas in plasma. Therapeutic drug monitoring, 1990, Volume: 12, Issue:4 Topics: Aged; Aged, 80 and over; Chlorpropamide; Chromatography, High Pressure Liquid; Female; Gliclazide; G	1990
Interaction between gliclazide and cimetidine. European journal of clinical pharmacology, 1987, Volume: 31, Issue:5 Topics: Aged; Cimetidine; Drug Interactions; Gliclazide; Humans; Hypoglycemia; Male; Sulfonylurea Compounds	1987

gliclazide and Fasting Hypoglycemia